Factors associated with the worsening of COVID-19 symptoms among cohorts in community- or home-isolation care in southern Thailand.

Thanit Sila, Wisanuwee Suriyaamorn, Chanavee Toh, Songyos Rajborirug, Smonrapat Surasombatpattana, Paramee Thongsuksai, Chanon Kongkamol, Sarunyou Chusri, Phoomjai Sornsenee, Prasit Wuthisuthimethawee, Raya Chaowanawong, Surasak Sangkhathat, Thammasin Ingviya
Author Information
  1. Thanit Sila: Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  2. Wisanuwee Suriyaamorn: Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  3. Chanavee Toh: Department of Health Science and Clinical Research, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  4. Songyos Rajborirug: Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  5. Smonrapat Surasombatpattana: Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  6. Paramee Thongsuksai: Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  7. Chanon Kongkamol: Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  8. Sarunyou Chusri: Department of Internal Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
  9. Phoomjai Sornsenee: Faculty of Medicine, Department of Family Medicine and Preventive Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand.
  10. Prasit Wuthisuthimethawee: Department of Emergency Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
  11. Raya Chaowanawong: Faculty of Nursing, Prince of Songkla University, Hat Yai, Songkla, Thailand.
  12. Surasak Sangkhathat: Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  13. Thammasin Ingviya: Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.

Abstract

Introduction: This study aimed to investigate factors associated with time-to-referral due to worsening symptoms in patients with laboratory-confirmed COVID-19 in southern Thailand. While underlying diseases have been evaluated to assess COVID-19 severity, the influence of vaccinations and treatments is also crucial.
Methods: A cohort of 8,638 patients quarantined in home or community isolation with laboratory-confirmed COVID-19 was analyzed. Survival analysis and the Cox proportional hazard ratio were employed to assess factors influencing time-toreferral.
Results: Age ��� 60 years, neurologic disorders, cardiovascular disease, and human immunodeficiency virus infection were identified as significant risk factors for severe COVID-19 referral. patients who received full- or booster-dose vaccinations had a lower risk of experiencing severe symptoms compared to unvaccinated patients. Notably, individuals vaccinated during the Omicron-dominant period had a substantially lower time-to-referral than those unvaccinated during the Delta-dominant period. Moreover, patients vaccinated between 1 and 6 months prior to infection had a significantly lower risk of time-to-referral than the reference group.
Discussion: These findings demonstrate early intervention in high-risk COVID-19 patients and the importance of vaccination efficacy to reduce symptom severity. The study provides valuable insights for guiding future epidemic management strategies and optimising patient care during infectious disease outbreaks.

Keywords

References

  1. Cardiovasc Res. 2020 May 1;116(6):1097-1100 [PMID: 32227090]
  2. Front Neurol. 2021 Jan 20;11:573095 [PMID: 33551947]
  3. JAMA Intern Med. 2020 Jul 1;180(7):934-943 [PMID: 32167524]
  4. Ann Transl Med. 2016 Apr;4(7):136 [PMID: 27162786]
  5. Lancet Respir Med. 2020 May;8(5):475-481 [PMID: 32105632]
  6. JAMA Neurol. 2020 Jun 1;77(6):683-690 [PMID: 32275288]
  7. J Neurol. 2021 Mar;268(3):762-769 [PMID: 32749601]
  8. Vaccines (Basel). 2021 Aug 04;9(8): [PMID: 34451982]
  9. Sci Immunol. 2022 Feb 18;7(68):eabn8014 [PMID: 35076258]
  10. JAMA. 2020 Mar 17;323(11):1061-1069 [PMID: 32031570]
  11. J Infect. 2020 Aug;81(2):e16-e25 [PMID: 32335169]
  12. Infect Drug Resist. 2021 Jun 15;14:2233-2239 [PMID: 34163188]
  13. JAMA Netw Open. 2021 Feb 1;4(2):e2037069 [PMID: 33533933]
  14. J Adv Nurs. 2021 Jan;77(1):308-317 [PMID: 33068024]
  15. Front Public Health. 2023 Aug 30;11:1190519 [PMID: 37719732]
  16. Nutr Today. 2015 May;50(3):117-128 [PMID: 27340299]
  17. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  18. J Allergy Clin Immunol. 2020 Jul;146(1):110-118 [PMID: 32294485]
  19. Front Public Health. 2021 Nov 30;9:775224 [PMID: 34917580]
  20. Vaccine. 2023 Apr 6;41(15):2447-2455 [PMID: 36803895]
  21. Clin Res Cardiol. 2020 May;109(5):531-538 [PMID: 32161990]
  22. Lancet HIV. 2021 Nov;8(11):e690-e700 [PMID: 34655550]
  23. Cureus. 2022 Jan 25;14(1):e21605 [PMID: 35228963]
  24. Am J Emerg Med. 2021 Aug;46:339-343 [PMID: 33067060]
  25. Lancet HIV. 2021 Jan;8(1):e24-e32 [PMID: 33316211]
  26. J Clin Med. 2023 Feb 09;12(4): [PMID: 36835923]
  27. JAMA. 2022 Apr 5;327(13):1286-1288 [PMID: 35175280]
  28. Lancet Respir Med. 2022 Apr;10(4):355-366 [PMID: 35085490]
  29. BMC Psychiatry. 2022 Jul 5;22(1):450 [PMID: 35790940]
  30. Lancet Glob Health. 2022 Jun;10(6):e798-e806 [PMID: 35472300]
  31. Int J Biol Macromol. 2022 Apr 15;204:161-168 [PMID: 35074332]
  32. PLoS One. 2021 Jun 29;16(6):e0253894 [PMID: 34185801]
  33. JAMA Netw Open. 2020 Sep 1;3(9):e2022310 [PMID: 32965502]
  34. Lancet. 2021 Jul 10;398(10295):121-130 [PMID: 34181880]
  35. Nutr Metab Cardiovasc Dis. 2020 Oct 30;30(11):1899-1913 [PMID: 32912793]
  36. Interface Focus. 2021 Oct 12;11(6):20210008 [PMID: 34956588]
  37. Clin Infect Dis. 2021 May 18;72(10):e558-e565 [PMID: 32856034]
  38. Lancet Reg Health Southeast Asia. 2023 Apr;11:100167 [PMID: 36785545]
  39. Saudi J Biol Sci. 2020 Oct;27(10):2531-2538 [PMID: 32336927]
  40. J Med Internet Res. 2021 Mar 9;23(3):e21064 [PMID: 33687341]
  41. Nat Med. 2021 Sep;27(9):1530-1535 [PMID: 34312554]
  42. Lancet. 2021 May 1;397(10285):1646-1657 [PMID: 33901420]
  43. J Med Virol. 2022 Apr;94(4):1294-1299 [PMID: 34796525]
  44. Science. 2022 Jan 21;375(6578):267-269 [PMID: 35050660]
  45. Clin Transl Sci. 2020 Nov;13(6):1077-1086 [PMID: 32315487]
  46. BMC Nephrol. 2023 May 22;24(1):140 [PMID: 37217840]
  47. Acta Biomed. 2022 Mar 14;93(1):e2022179 [PMID: 35315394]
  48. Int J Antimicrob Agents. 2020 Aug;56(2):106054 [PMID: 32534188]
  49. BMJ. 2022 Apr 25;377:o1052 [PMID: 35470224]
  50. BMJ Open. 2021 Jun 15;11(6):e047007 [PMID: 34130961]
  51. Lancet Neurol. 2020 Nov;19(11):919-929 [PMID: 33031735]
  52. Nat Rev Microbiol. 2021 Mar;19(3):141-154 [PMID: 33024307]
  53. N Engl J Med. 2021 Feb 4;384(5):481-483 [PMID: 33378608]
  54. Arch Virol. 2023 Jan 3;168(1):26 [PMID: 36593392]
  55. Fam Med Community Health. 2020 Feb 16;8(1):e000262 [PMID: 32148735]
  56. Sports Med Health Sci. 2020 Jun;2(2):55-64 [PMID: 34189484]
  57. JAMA Netw Open. 2022 Sep 1;5(9):e2232760 [PMID: 36136332]
  58. Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015 [PMID: 32860699]
  59. Stroke Vasc Neurol. 2020 Jun;5(2):146-151 [PMID: 32385132]
  60. Vaccines (Basel). 2022 Feb 23;10(3): [PMID: 35334982]
  61. Lancet Reg Health Eur. 2023 Feb;25:100556 [PMID: 36530491]
  62. Int J Infect Dis. 2020 May;94:91-95 [PMID: 32173574]
  63. J Family Med Prim Care. 2021 Nov;10(11):3956-3963 [PMID: 35136752]
  64. Eur J Heart Fail. 2020 May;22(5):911-915 [PMID: 32275347]
  65. Circulation. 2020 May 19;141(20):1648-1655 [PMID: 32200663]
  66. J Med Internet Res. 2020 Jul 2;22(7):e19514 [PMID: 32568727]
  67. Front Public Health. 2023 Jan 10;10:1023431 [PMID: 36703817]
  68. BMJ Open. 2021 Feb 18;11(2):e044618 [PMID: 33602714]
  69. Int J Infect Dis. 2020 Oct;99:496-504 [PMID: 32800858]
  70. EClinicalMedicine. 2022 Mar 12;46:101344 [PMID: 35295900]
  71. Trends Pharmacol Sci. 2004 Jun;25(6):291-4 [PMID: 15165741]
  72. N Engl J Med. 2020 Dec 31;383(27):2603-2615 [PMID: 33301246]
  73. AIDS Res Ther. 2022 Jan 14;19(1):3 [PMID: 35031068]
  74. Nat Rev Cardiol. 2020 May;17(5):259-260 [PMID: 32139904]
  75. Int J Stroke. 2020 Jun;15(4):385-389 [PMID: 32310015]
  76. Eur Respir J. 2020 May 7;55(5): [PMID: 32269088]

MeSH Term

Humans
Middle Aged
Thailand
COVID-19
Patient Isolation
Quarantine
Cardiovascular Diseases

Word Cloud

Created with Highcharts 10.0.0COVID-19patientstime-to-referralfactorssymptomsThailandrisklowerstudyassociatedworseninglaboratory-confirmedsouthernassessseverityvaccinationsdiseaseinfectionsevereunvaccinatedvaccinatedperiodcarehome-isolationIntroduction:aimedinvestigatedueunderlyingdiseasesevaluatedinfluencetreatmentsalsocrucialMethods:cohort8638quarantinedhomecommunityisolationanalyzedSurvivalanalysisCoxproportionalhazardratioemployedinfluencingtime-toreferralResults:Age���60yearsneurologicdisorderscardiovascularhumanimmunodeficiencyvirusidentifiedsignificantreferralPatientsreceivedfull-booster-doseexperiencingcomparedNotablyindividualsOmicron-dominantsubstantiallyDelta-dominantMoreover16monthspriorsignificantlyreferencegroupDiscussion:findingsdemonstrateearlyinterventionhigh-riskimportancevaccinationefficacyreducesymptomprovidesvaluableinsightsguidingfutureepidemicmanagementstrategiesoptimisingpatientinfectiousoutbreaksFactorsamongcohortscommunity-Southerncommunity-isolationvaccine

Similar Articles

Cited By (1)